Strong Momentum Drives Venus Remedies to New Heights
On 3 December 2025, Venus Remedies touched an intraday high of Rs.799.4, marking its highest price level in the past year and setting an all-time peak. The stock has recorded gains for three consecutive days, accumulating a return of 14.22% during this period. This rally has outpaced the Pharmaceuticals & Biotechnology sector by 3.72% on the day, signalling notable relative strength.
The stock's performance is further highlighted by its position above key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Such technical positioning often indicates sustained buying interest and a positive trend in price action.
Despite a broader market setback, with the Sensex declining by 224.44 points to close at 84,926.20 (-0.25%), Venus Remedies has demonstrated resilience. The benchmark index remains close to its own 52-week high, trading just 1.45% below the peak of 86,159.02, and maintains a bullish stance above its 50-day and 200-day moving averages.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Year-on-Year Performance and Financial Highlights
Venus Remedies has exhibited a remarkable one-year performance, with its stock price appreciating by 148.43%, significantly outstripping the Sensex's 5.03% return over the same period. The stock's 52-week low was recorded at Rs.272.2, illustrating the extent of its upward trajectory.
Financially, the company has reported a net profit growth of 473.5% in the latest results, with positive outcomes declared for four consecutive quarters. The profit after tax (PAT) for the latest six months stands at Rs.29.73 crores, reflecting a growth of 528.54%. Additionally, the profit before tax excluding other income (PBT less OI) for the quarter is Rs.24.78 crores, showing a substantial increase of 2073.68%.
Return on capital employed (ROCE) for the half year is noted at 13.99%, while the return on equity (ROE) is 10.5%. The company maintains a low debt-to-equity ratio, averaging zero, which indicates a conservative capital structure.
Valuation metrics reveal a price-to-book value of 1.7, positioning Venus Remedies at a fair value relative to its peers' historical averages. The price-to-earnings-to-growth (PEG) ratio stands at 0.1, reflecting the relationship between earnings growth and valuation.
Want to dive deeper on Venus Remedies ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Market Position and Sector Context
Venus Remedies operates within the Pharmaceuticals & Biotechnology sector, which has seen varied performance in recent sessions. The stock's ability to outperform its sector peers by 3.72% on the day of the new high highlights its relative strength. Over the past three years, the stock has consistently outperformed the BSE500 index, reinforcing its market standing.
The company's market capitalisation grade is noted at 4, reflecting its size and market presence. Despite this, domestic mutual funds hold no stake in Venus Remedies, a factor that may reflect differing assessments of the company's valuation or business prospects.
Overall, Venus Remedies' recent price action and financial results illustrate a period of strong momentum and significant value creation for shareholders, as evidenced by the new 52-week high and robust growth metrics.
Summary of Key Metrics
• New 52-week and all-time high price: Rs.799.4
• Three-day consecutive gains with 14.22% returns
• Outperformance of sector by 3.72% on the day
• One-year stock return: 148.43% versus Sensex 5.03%
• Net profit growth: 473.5%
• PAT (latest six months): Rs.29.73 crores (growth of 528.54%)
• PBT less other income (quarterly): Rs.24.78 crores (growth of 2073.68%)
• ROCE (half year): 13.99%
• ROE: 10.5%
• Price to book value: 1.7
• Debt to equity ratio: 0 (average)
Venus Remedies' achievement of a new 52-week high at Rs.799.4 is a clear indicator of its upward trajectory in the current market cycle. The stock's sustained gains, supported by strong financial performance and favourable valuation metrics, have contributed to this milestone.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
